ModifiSite™ Monoamine Oxidase Assay Kit

CAT#: ITS-1125-HM130
Product Type: Assay Kit
Species: All Species
Brand: ModifiSite
Development Stage: Research-Grade Protein & Enzyme Assay Development
Short Description
Measures MAO activity (A/B isoforms).
Brand
ModifiSite
Development Stage
Research-Grade Protein & Enzyme Assay Development
Description
The ModifiSite™ Monoamine Oxidase Assay Kit utilizes fluorometric H2O2 detection to validate MAO-A/B inhibitors for depression and Parkinson's disease. This assay screens for compounds that modulate neurotransmitter degradation in the brain. It supports neuropharmacology research by quantifying the activity of key enzymes in dopamine and serotonin metabolism.
Features
Fluorometric H2O2 detection; Validates MAO-A/B inhibitors for depression and Parkinson's disease.
Process Relevance
CNS Drug Discovery
Application Stage
Lead Optimization
Applications
Neurological disorders and MAO inhibitor screening.
Qualified With
Internal performance validation using reference standards under defined assay conditions.
Detection Method
Fluorescence Detection (Ex 530 nm / Em 585 nm)
Sample Type
MAO enzyme preparations
Research Areas
Neuroscience; Psychiatry
Size
100 tests
Data Output Type
Kinetic (Enzyme Activity)
Assay Time
Results in 30 min
LOD
0.01 U/L
Species
All Species
Storage
Store at −20 °C upon receipt to maintain reagent stability. Follow recommended handling procedures to ensure consistent assay performance.
Storage Comment
Avoid repeated freeze-thaw cycles. During use, minimize the time components are exposed to room temperature and return them promptly to −20 °C storage after handling. Do not store at elevated temperatures for extended periods.
Expiry Date
6 months under recommended storage conditions to ensure optimal performance.
Note
For bulk pricing or custom reagent inquiries, please contact us by email or phone. Products are shipped on ice via FedEx.
Restrictions
For Research Use Only (RUO). Not intended for diagnostic or therapeutic use.
Shipping
Shipped on ice under temperature-controlled conditions.
Background
Monoamine Oxidases (MAO) degrade neurotransmitters like serotonin and dopamine. MAO inhibitors are established treatments for depression and Parkinson's disease.
For Research Use Only | Not For Clinical Use
Online Inquiry